BioSpace News Archive

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring systems for people with diabetes, announced that it plans to release its second quarter 2021 financial results after market close on Monday, August 9, 2021.

Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 72,800 shares of the Company’s common stock at an exercise price per share of $32.85, which was the closing price on July 23, 2021.

Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced the pricing of its initial public offering of 9,000,000 shares of common stock at a public offering price of $8.00 per share.

Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that, following a hearing before the Irish High Court, it has scheduled special shareholder meetings for Wednesday, September 8, 2021, in connection with the proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc.

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced that it will release second quarter financial results after the close of trading on Monday, August 2, 2021.

EyeGate Pharmaceuticals, Inc. announced that Brian M Strem, Ph.D., Co-Founder, Director and former Chief Executive Officer of Okogen, Inc as well as Co-Founder and Managing Director of Bayon Therapeutics, was appointed as permanent President, Chief Executive Officer and board member, effective immediately.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the second quarter of 2021 after market close on Monday, August 9, 2021.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after market close on Thursday, August 5, 2021.

Race, in combination with other factors, predicted how quickly individuals with stroke got to stroke centers to receive necessary neuroendovascular stroke surgery, according to research presented at the Society of NeuroInterventional Surgery’s 18th Annual Meeting.

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Japan SLC, Inc., a biotechnology company providing animal models to the research community, announced a non-exclusive license agreement granting Japan SLC access to ERS Genomics’ CRISPR/Cas9 patent portfolio.